Safety and immunogenicity of a recombinant hepatitis B vaccine administered to infants at 2, 4 and 6 months of age

Vaccine

Volumn 14, Issue 8, 1996, Pages 811-816

  Greenberg, David P ^a   Vadheim, Constance M ^a   Marcy, S Michael ^c   Partridge, Susan ^a   Jing, Jennie ^a   Chiu, Chung Yin ^a   Greene, Tracy ^b   Margolis, Harold S ^b   Ward, Joel I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NONE

Author keywords

Hepatitis B vaccine; Immunization; Infants; Vaccine safety

Indexed keywords

RECOMBINANT HEPATITIS B VACCINE;

ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

EID: 0030175813     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00228-S     Document Type: Article

References (36)

1. 1 Centers for Disease Control. Recommendations for protection against viral hepatitis. Morbid. Mortal. Wkly Rep. 1985, 34, 313-335
2. 2 Centers for Disease Control. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). Morbid. Mortal. Wkly Rep. 1991, 40, 1-25
3. 3 American Academy of Pediatrics, Committee on Infectious Diseases. Universal hepatitis B immunization. Pedatrics 1992, 89, 795-800
4. 4 André, F.E. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am. J. Med. 1989, 87Suppl 3A, 14S-20S
5. 5 West, D.J. Clinical experience with hepatitis B vaccines. Am. J. Infect. Control 1989, 17, 172-180
6. 6 Hadler, S.C. and Margolis, H.S. Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. Curr. Clin. Top. Infect. Dis. 1992, 12, 282-308
7. 7 Greenberg, D.P. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. Ped. Infect. Dis. J. 1993, 12, 438-445
8. 8 Jilg, W., Schmidt, M. and Deinhardt, F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J. Infect. Dis. 1989, 160, 766-769
9. 9 Vadheim, C.M., Greenberg, D.P., Partridge, S., Jing, J., Ward, J.I. and Kaiser-UCLA Vaccine Study Group. Effectiveness and safety of an Haemophilus influenzae type b conjugate vaccine (PRP-T) in young infants. Pediatrics 1993, 92, 272-279
10. 10 Greenberg, D.P., Vadheim, C.M., Partridge, S. et al. Immunogenicity of Haemophilus influenzae type b tetanus toxoid conjugate vaccine (PRP-T) in young infants. J. Infect. Dis. 1994, 170, 76-81
11. 11 Dixon, W.J., Brown, M.B., Engelman, L. and Jennrich, R.I. (Eds) BMDP Statistical Software. University of California Press, Berkeley, CA, 1990
12. 12 Stevens, C.E., Taylor, P.E., Tong, M.J. et al. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. J. Am. Med. Assoc. 1987, 257, 2612-2616
13. 13 Cody, C.L., Baraff, L.J., Cherry, J.D., Marcy, S.M. and Manclark, C.R. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981, 68, 650-660
14. 14 Barkin, R.M. and Pichichero, M.E. Diphtheria-pertussis-tetanus vaccine: reactogenicity of commercial products. Pediatrics 1979, 63, 256-260
15. 15 Long, S.S., Deforest, A., Pennridge Pediatric Associates, Smith, D.G., Lazaro, C. and Wassilak, S.G.F. Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy. Pediatrics 1990, 85, 294-302
16. 16 Baraff, L.J., Cody, C.L. and Cherry, J.D. DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose. Pedatrics 1984, 73, 31-36
17. 17 Verschoor, P.L., Wilschut, J.T., de Jonge, G.A. and Kostense, P.J. Frequent symptoms after DTPP vaccinations. Archs. Dis. Child. 1991, 66, 1408-1412
18. 18 Peterson, D.R. Evolution of the epidemiology of the sudden infant death syndrome. Epidemiol. Rev. 1980, 2, 97-112
19. 19 Institute of Medicine Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines. In: Adverse Effects of Pertussis and Rubella Vaccines (Eds Howson, C.P., Howe, C.J. and Fineberg, H.V.). National Academy Press, Washington, DC, 1991, pp. 65-124
20. 20 van den Berg, B.J. and Yerushalmy, J. Studies on convulsive disorders in young children, I: incidence of febrile and nonfebrile convulsions by age and other factors. Ped. Res. 1969, 3, 298-304
21. 21 Ellenberg, J.H., Hirtz, D.G. and Nelson, K.B. Age at onset of seizures in young children. Ann. Neurol. 1984, 15, 127-134
22. 22 Gunn, T.R., Bosley, A. and Woodfield, D.G. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates. N.Z. Med. J. 1989, 102, 1-3
23. 23 Poovorawan, Y., Sanpavat, S., Pongpunlert, W. et al. Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B vaccine immune globulin for the prevention of perinatal acquisition of hepatitis B carriage. Vaccine 1990, 8Suppl., S56-S59
24. 24 Wainwright, R.B., McMahon, B.J., Bulkow, L.R., Parkinson, A.J. and Harpster, A.P. Protection provided by hepatitis B vaccine in a Yupik Eskimo population. Arch. Intern. Med. 1991, 151, 1634-1636
25. 25 Hadler, S.C., Francis, D.P., Maynard, J.E. et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N. Engl. J. Med. 1986, 315, 209-214
26. 26 Lo, K.-J., Lee, S.-D., Tsai, Y.-T. et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in infants born to HBeAg-positive HBsAg-carrier mothers. Hepatology 1988, 8, 1647-1650
27. 27 Coursaget, P., Yvonnet, B., Chotard, J. et al. Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet 1986, 2, 1143-1145
28. 28 Lieming, D., Mintai, Z., Yinfu, W., Shaochon, Z., Weiqin, K. and Smego, R.A. A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk chinese neonates. Clin. Infect. Dis. 1993, 17, 475-479
29. 29 Xu, Z.-Y., Duan, S.-C., Margolis, H.S. et al. Long-term efficacy of active postexposure immunization of infants for prevention of hepatitis B virus infection. J. Infect. Dis. 1995, 171, 54-60
30. 30 Huang, L.-M., Lee, C.-Y., Hsu, C.-Y. et al. Effect of monovalent measles and trivalent measles-mumps-rubella vaccines at various ages and concurrent administration with hepatitis B vaccine. Ped. Infect. Dis. J. 1990, 9, 461-465
31. 31 Chiron, J.P., Coursaget, P., Yvonnet, B. et al. Simultaneous administration of hepatitis B and diphtheria/tetanus/polio vaccines. Lancet 1984, 1, 623-624
32. 32 Coursaget, P., Yvonnet, B., Relyveld, E.H., Barres, J.L., Diop-Mar, I. and Chiron, J.P. Simultanous administration of diphtheria-tetanus-pertussis-polio and hepatitis B vaccines in a simplified immunization program: immune response to diphtheria toxoid, tetanus toxoid, pertussis, and hepatitis B surface antigen. Infect. Immun. 1986, 51, 784-787
33. 33 Yvonnet, B., Coursaget, P., Deubel, V., Diop-Mar, I., Digoutte, J.P. and Chiron, J.P. Simultaneous administration of hepatitis B and yellow fever vaccines. J. Med. Virol. 1986, 19, 307-311
34. 34 Coursaget, P., Bringer, L., Bourdil, C. et al. Simultaneous injection of hepatitis B and measles vaccines. Trans. R. Soc. Trop. Med. Hyg. 1991, 85, 788
35. 35 Barone, P., Mauro, L., Leonardi, S. et al. Simultaneous administration of HB recombinant vaccine with diphtheria and tetanus toxoid and oral polio vaccine: a pilot study. Acta. Paed. Jpn. 1991, 33, 455-458
36. 36 Giammanco, G., Li Volti, S., Mauro, L. et al. Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccines in infancy. Vaccine 1991, 9, 747-750